Monday, June 22, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 1034 of 1,261

  1. AR 065042

    DERIVADOS DE CINNOLINA, PROCESOS DE OBTENCION Y COMPOSICIONES FARMACEUTICAS

    ASTRAZENECA AB [SE] · Granted May 13, 2009 · Expires May 8, 2029

    granted

  2. US 7531523

    Sodium channel protein type III alpha-subunit splice variant

    Vertex Pharmaceuticals Incorporated · Granted May 12, 2009 · Expires May 7, 2029

    granted

  3. US 7531556

    Compositions useful as inhibitors of rock and other protein kinases

    Vertex Pharmaceuticals Incorporated · Granted May 12, 2009 · Expires May 7, 2029

    granted

  4. US 7531536

    Pyrazole compounds useful as protein kinase inhibitors

    Vertex Pharmaceuticals Incorporated · Granted May 12, 2009 · Expires May 7, 2029

    granted

  5. US 7531500

    Preventing airway mucus production by administration of EGF-R antagonists

    The Regents of the University of California · Granted May 12, 2009 · Expires May 7, 2029

    granted

  6. US 7531514

    Orally administered peptides synergize statin activity

    The Regents of the University of California · Granted May 12, 2009 · Expires May 7, 2029

    granted

  7. US 7531355

    Methods and compositions for smooth muscle reconstruction

    The Regents of the University of California · Granted May 12, 2009 · Expires May 7, 2029

    granted

  8. US 7531352

    Inducible plasmid vector encoding TGF-β and use thereof

    The United States of America, as represented by the Department of Health and Human Services · Granted May 12, 2009 · Expires May 7, 2029

    granted

  9. US 7531173

    Ophthalmic composition of a VEGF antagonist

    REGENERON PHARMACEUTICALS, INC. · Granted May 12, 2009 · Expires May 7, 2029

    granted

  10. US 7531172

    Methods of treating diseases with a VEGF antagonist

    REGENERON PHARMACEUTICALS, INC. · Granted May 12, 2009 · Expires May 7, 2029

    granted

  11. US 7531162

    Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation

    Regents of the University of Minnesota · Granted May 12, 2009 · Expires May 7, 2029

    granted

  12. US 7531341

    Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof

    BIOMARIN PHARMACEUTICAL INC. · Granted May 12, 2009 · Expires May 7, 2029

    granted

  13. US 7531635

    MATER-protein specific antibodies and methods of use

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted May 12, 2009 · Expires May 7, 2029

    granted

  14. US 7531570

    Treatment of diseases using ICE inhibitors

    Vertex Pharmaceuticals Incorporated · Granted May 12, 2009 · Expires May 7, 2029

    granted

  15. US 7531623

    Hydrochloride salts of a glycopeptide phosphonate derivative

    Theravance, Inc. · Granted May 12, 2009 · Expires May 7, 2029

    granted

  16. US 7531656

    Synthesis of gatifloxacin

    Teva Pharmaceuticals USA, Inc. · Granted May 12, 2009 · Expires May 7, 2029

    granted

  17. US 7527786

    Methods for inhibiting the growth of cancer cells expressing PSCA

    The Regents of the University of California · Granted May 5, 2009 · Expires Apr 30, 2029

    granted

  18. US 7527802

    Vaccine for transcutaneous immunization

    The United States of America as represented by the Secretary of the Army · Granted May 5, 2009 · Expires Apr 30, 2029

    granted

  19. US 7527934

    Labeled substrate conjugates for identifying enzyme inhibitors

    The Regents of the University of California · Granted May 5, 2009 · Expires Apr 30, 2029

    granted

  20. US 7528138

    Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases

    Vertex Pharmaceuticals Incorporated · Granted May 5, 2009 · Expires Apr 30, 2029

    granted

  21. US 7528202

    Poly (ethylene glycol) derivatives with proximal reactive groups

    Nektar Therapeutics AL, Corporation · Granted May 5, 2009 · Expires Apr 30, 2029

    granted

  22. US 7528253

    Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity

    Theravance, Inc. · Granted May 5, 2009 · Expires Apr 30, 2029

    granted

  23. US 7527797

    Vibrio cholerae 0139 conjugate vaccines

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted May 5, 2009 · Expires Apr 30, 2029

    granted

  24. US 7528118

    RNAi modulation of ApoB and uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted May 5, 2009 · Expires Apr 30, 2029

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.